ZTS · Zoetis Inc.

Zoetis Inc ZTS

Develops and sells medicines, vaccines, and diagnostic products for livestock and companion animals.

Industry
Pharmaceuticals
Listed on
New York Stock Exchange
IPO
2013-02-01
Website
zoetis.com

Daily brief

Zoetis Slides as 2026 Guidance Cut Triggers Wave of Analyst Downgrades

+2.99% to $74.83 from $72.66

What moved ZTS

  • Zoetis cut its 2026 revenue forecast to a range of $9.12 billion to $9.32 billion, down from a prior range of $9.68 billion to $9.96 billion, and lowered adjusted EPS guidance to $6.15-$6.25 from $6.85-$7.00.
  • The company cited mounting pressure in its companion-animal segment, where U.S. revenue fell 7% in the quarter amid fewer veterinary clinic visits, more price-sensitive pet owners and intensifying competition.
  • UBS moved its rating on Zoetis to ‘Neutral’ and cut its price target to $85 from $99, while Piper Sandler cut its target to $80 from $90, part of a broader downgrade wave following the outlook cut.
  • The guidance reduction coincided with a change in Zoetis’s finance leadership, adding to investor uncertainty about near-term execution.

Sources: ad-hoc-news.de · Simply Wall St

More on Zoetis Inc.

Financial history →

← All stocks

This content is for informational purposes only and is not investment advice. Always do your own research before making financial decisions.